S&P 500 Hits New High on Apple Earnings: Stock Market Today

Why It Matters

Apple’s strong results and capital return program buoyed the broader market, underscoring consumer tech’s resilience, while Atlassian’s cloud momentum highlights AI‑driven software growth and Amgen’s regulatory risk reminds investors of biotech volatility.

Key Takeaways

• Apple revenue up 22% on iPhone sales, boosting S&P 500
• Apple announced $100 billion buyback and 4% dividend increase
• Atlassian shares jumped 30% after 32% revenue growth
• Atlassian raised full‑year cloud revenue outlook to 26.5% YoY
• Amgen stock fell 5% despite earnings beat, FDA concerns linger

Pulse Analysis

Apple’s second‑quarter earnings sparked a market rally, pushing the S&P 500 to a new high and reinforcing the index’s reliance on mega‑cap tech. The 22% YoY rise in iPhone revenue, bolstered by a 28% surge in China, signals renewed consumer demand after a period of softness. Coupled with a $100 billion share‑buyback and a 4% dividend increase, Apple’s capital‑return strategy signals confidence and provides a catalyst for investors seeking both growth and income. Analysts also anticipate AI‑driven product announcements at WWDC, which could further elevate the stock.

Atlassian’s earnings painted a contrasting picture of rapid expansion in the enterprise software space. Revenue jumped 32% to $1.79 billion, driven by a 29% lift in cloud services and a 44% surge in data‑center offerings, reflecting strong customer adoption of AI‑enhanced tools. The company’s upgraded full‑year guidance—26.5% cloud growth and 21.5% data‑center growth—positions it as a beneficiary of the broader AI migration in business IT. Valuation analysts note that despite a 46% YTD decline, the stock’s current price offers a compelling entry point given its strategic positioning.

Amgen’s mixed outcome underscores the delicate balance biotech firms face between earnings performance and regulatory risk. While the firm beat earnings and lifted its full‑year outlook, the FDA’s proposal to withdraw approval for its Tavneos drug introduced uncertainty, tempering investor enthusiasm and dragging the stock down 5%. Nonetheless, analysts highlight Amgen’s pipeline, especially the obesity and Type 2 diabetes candidate MariTide, as a growth engine that could offset short‑term setbacks. The episode illustrates how regulatory developments can swiftly impact market sentiment in the healthcare sector, reinforcing the need for diversified pipelines.